Abstract: A chemical reaction system is disclosed for use in a device for delivering a therapeutic fluid comprising a liquid base and a polymeric acid. A reaction rate of the chemical reaction system is capable of being adjusted by adjusting at least one of surface area-to-volume ratio, acid concentration, and cross-linking of the polymeric acid.

Abstract: A medication delivery device is disclosed including a rack-and-pinion plunger drive system. The drive system includes an output drive having a pawled end movably coupled with the ratchet teeth of the plunger, and a pinion drive coupled between the housing, the output drive and an actuator. Actuator is longitudinally movable between dose set and delivery positions. Movement of the actuator causes rotation of the pinion drive along the rack to translate the output drive member with the pawled end that is engaged with the plunger ratchet teeth to distally advance the plunger. The device may include one or more of an end of dose mechanism to limit travel of the actuator, a load brake system to stop travel of the plunger under high input forces, a dose detection system, and a dose selector to vary the amount of dose set.

Abstract: A drug delivery system includes a drug containing device and a drug delivery device. The drug containing device includes a chamber carrying a fluid drug and an outlet in fluid communication with the chamber. A first closure initially inhibits the fluid drug from exiting the drug containing device via the outlet. The drug delivery device includes a fluid passageway and a stem having an inlet in fluid communication with the fluid passageway. The stem displaces the first closure from the outlet and enters the outlet to provide fluid communication between the chamber and the fluid passageway and thereby facilitates delivery of the fluid drug to the drug delivery device. A second closure is coupled to the stem, and the second closure engages the first body at the outlet when the stem enters the outlet to inhibit the fluid drug from exiting the drug containing device around the stem.

Abstract: The present invention provides a compound of Formula I. or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

Abstract: The present disclosure provides human CD33 antibodies and antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of myeloid cell associated diseases.

Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.

Abstract: The present invention provides a method of treating symptoms associated with Androgen Deprivation Therapy comprising administering to a patient in need of such treatment an effective amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.

Abstract: The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.

Abstract: Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.

Abstract: Provided herein are RET kinase inhibitors according to the formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R1, n, X1, X2, X3, X4, and R2 have the meanings given in the specification.

Abstract: A medication delivery device usable with a medication container wherein advancement of a piston within the container expels medication. The device includes a housing and a drive assembly. The drive assembly includes a drive ribbon having distal and proximal edge sections. The drive ribbon has a retracted configuration defining a spiral and an extended configuration defining a helix. The drive ribbon is movable from the retracted configuration to the extended configuration with the movement defining a drive axis and advancing the piston. In some embodiments, the drive ribbon may not rotate as the drive ribbon is advanced while in other embodiments, the ribbon does rotate. Disclosed drive assemblies include manually driven assemblies, spring driven assemblies and motor driven assemblies. The container may be replaceable to allow for reuse of the device. In some embodiments, replaceable cartridges which include both the medication container and the drive ribbon are employed.

Abstract: An injection device assembly including a housing, a syringe, a drive mechanism and a status sensing system and a module are described. The drive mechanism advances the syringe from a storage position to an injection position, and a plunger advances the syringe piston from an initial position to a final position. The status sensing system includes a light emitter that emits electromagnetic radiation into the housing transverse to the longitudinal axis, a light detector and a controller. The system determines a current status condition from at least three of the following five status conditions: 1) an injection ready state; 2) a needle insertion state; 3) a drug delivered state; 4) a needle guard present state; and 5) a needle retraction state.

Abstract: An injection device assembly including a housing, a syringe, a drive mechanism and one or more sensing systems are described. The drive mechanism advances the syringe from a storage position to an injection position, and a plunger advances the syringe piston from an initial position to a final position. The status sensing system may include one or more main PCB(s) disposed in an end portion of the injection device assembly's housing. The system may determine various parameters related to an operational status of the injection device, including the location of the device's components, an amount of medication remaining in the device, a temperature of the medication, and whether or not the device is properly contacting the user's skin before injection. The system may communicate such determined parameters to an external device via a wireless communication link.